The firstinhuman study of the panPIM kinase inhibitor PIM447 in patients with relapsed andor refractory multiple myeloma

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

13:51 EDT 15 May 2019 | Nature Publishing

More From BioPortfolio on "The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma"